With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
That’s never proven to be a vaguer term than during this pandemic. The ABS wants you to know, in case you were wondering, brachytherapy for cervical and high-risk prostate cancers is not elective. | ABS 2020